Northern Trust’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-25,533
| Closed | -$85K | – | 4306 |
|
|
2019
Q4 | $85K | Sell |
25,533
-40
| -0.2% | -$127 | ﹤0.01% | 3964 |
|
|
2019
Q3 | $78K | Buy |
25,573
+2,777
| +12% | +$7.81K | ﹤0.01% | 3973 |
|
|
2019
Q2 | $54K | Sell |
22,796
-22
| -0.1% | -$66 | ﹤0.01% | 4071 |
|
|
2019
Q1 | $86K | Sell |
22,818
-453
| -2% | -$1.7K | ﹤0.01% | 3951 |
|
|
2018
Q4 | $84K | Sell |
23,271
-462
| -2% | -$2.01K | ﹤0.01% | 3960 |
|
|
2018
Q3 | $136K | Buy |
23,733
+8,098
| +52% | +$46.3K | ﹤0.01% | 3962 |
|
|
2018
Q2 | $78K | Buy |
15,635
+2,681
| +21% | +$13.8K | ﹤0.01% | 4056 |
|
|
2018
Q1 | $66K | Sell |
12,954
-280
| -2% | -$1.69K | ﹤0.01% | 4046 |
|
|
2017
Q4 | $80K | Buy |
+13,234
| New | +$79.6K | ﹤0.01% | 4013 |
|
|
2016
Q4 | – | Sell |
-24,091
| Closed | -$223K | – | 4220 |
|
|
2016
Q3 | $223K | Buy |
+24,091
| New | +$201K | ﹤0.01% | 3701 |
|
|
2016
Q2 | – | Sell |
-205,644
| Closed | -$1.34M | – | 4292 |
|
|
2016
Q1 | $1.34M | Buy |
205,644
+444
| +0.2% | +$2.86K | ﹤0.01% | 3156 |
|
|
2015
Q4 | $1.66M | Buy |
205,200
+7,214
| +4% | +$53.9K | ﹤0.01% | 3148 |
|
|
2015
Q3 | $1.45M | Buy |
197,986
+179,457
| +969% | +$1.83M | ﹤0.01% | 3193 |
|
|
2015
Q2 | $190K | Buy |
+18,529
| New | +$205K | ﹤0.01% | 3793 |
|
Northern Trust's FOMX Position: Q1 2020 in Review
Northern Trust sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 25,533 shares — an estimated $85K sold.
Northern Trust first reported a position in FOMX in Q2 2015 and held it in 14 quarters. The position peaked at $1.66M in Q4 2015. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- Northern Trust reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- Northern Trust sold 25,533 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $85K.
- Northern Trust first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 14 quarters.
- Northern Trust's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $1.66M in Q4 2015.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on Northern Trust's 13F filing for Q1 2020, filed 14 May 2020.